Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Ocular Therapeutix Jumped 21.6% in August

By Maxx Chatsko - Sep 10, 2018 at 12:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reported second-quarter 2018 financial results and an important business update.

What happened

Shares of Ocular Therapeutix ( OCUL -5.38% ) gained 21.6% last month, according to data provided by S&P Global Market Intelligence. The eye drug specialist reported second-quarter and first-half 2018 results. Considering it only has one commercialized product on the market, it doesn't have much to show on its income statements, but investors were comforted to know that the business exited June 2018 with nearly $57 million in cash and cash equivalents.

That could come in handy. Ocular Therapeutix announced that its new drug application (NDA) resubmission for Dextenza, a treatment for postoperative inflammation and pain, was accepted by the U.S. Food and Drug Administration at the end of June. The drug candidate has a PDUFA date of December 28, which is when the regulatory body will rule on the product's future.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

Ocular Therapeutix has seen its market valuation double since the beginning of the year, as investors grow more excited about the company's potential to become a bona fide commercial-stage operation. Receiving marketing approval for Dextenza would be the biggest win yet for the company on that front, although there are two other drug candidates currently in phase 3 trials.

Now what

That said, the eye specialist is still valued at less than $300 million, which hints that Mr. Market still isn't very enthusiastic about the company's prospects. That could change as the PDUFA date approaches, but investors shouldn't get too carried away just yet. With a net loss of $27.5 million in the first half of 2018, failing to receive marketing approval or to successfully commercialize Dextenza could hurt investors betting on a positive outcome at the end of the year.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocular Therapeutix, Inc. Stock Quote
Ocular Therapeutix, Inc.
OCUL
$6.16 (-5.38%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.